8285

US drug maker Mylan enters Indian market

The drug maker plans to start with HIV drugs in the local market
Comment E-mail Print Share
First Published: Mon, Aug 06 2012. 04 10 PM IST
Mylan is looking to tap into the significant growth potential of India’s pharmaceutical market, the world’s second largest by volume. Photo: Hemant Mishra/Mint
Mylan is looking to tap into the significant growth potential of India’s pharmaceutical market, the world’s second largest by volume. Photo: Hemant Mishra/Mint
Also Read

Story Highlights

  • Mylan has been a leader in the global anti-retroviral market for nearly a decade
  • Of the 2.4 million AIDS patients in India, fewer than 20% have access to treatment
  • Company’s manufacturing plant at Nashik in Maharashtra produces finished-dosage-form ARVs for markets around the world
Updated: Tue, Aug 14 2012. 03 27 PM IST
Mumbai: US generic drug maker Mylan Inc. said on Monday that its unit Mylan Pharmaceuticals Pvt. Ltd has started commercial operations in India with the launch of 18 anti-retroviral (ARV) products for the treatment of HIV/AIDS.
In 2006, Mylan acquired a majority stake in Hyderabad-based Matrix Laboratories Ltd and the Indian company continued supplying active pharma ingredients to the US company and a few of its foreign clients. After acquiring a 100% stake in Matrix Laboratories, Mylan de-listed the Indian entity, which was still not present in the local pharmaceutical market.
photoMint had in May 2011 reported Mylan’s plan to directly enter the Indian drug formulation market through the acquired entity by renaming it Mylan Pharmaceuticals.
Mylan’s strategy to start with HIV drugs in the local market is strategic as the country is home to the world’s third-largest population of HIV/AIDS patients, with about 2.4 million people affected by the disease, said an analyst with a foreign brokerage.
Of these 2.4 million AIDS patients in India, fewer than 20% have access to treatment, Mylan said in a statement on Monday.
“We see significant growth potential in India, the world’s second largest pharmaceutical market by volume, and look forward to continuing to expand our operations in India in additional therapeutic categories,” Mylan’s chief executive officer Heather Bresch said in the statement.
Mylan has been a leader in the global anti-retroviral market for nearly a decade.
“Mylan has helped to significantly drive down the cost of ARV therapies,” said Rajiv Malik, president of Mylan Pharmaceuticals. “We now offer a portfolio of 43 ARV drugs, and the launch of 18 of these products in India represents an exciting first step in this important market,” he said.
The company’s manufacturing plant at Nashik in Maharashtra, which produces the company’s finished-dosage-form ARVs for markets around the world, including India, has been subject to quality inspections by regulatory authorities, including the US Food and Drug Administration, and the World Health Organization.
Comment E-mail Print Share
First Published: Mon, Aug 06 2012. 04 10 PM IST
More Topics: Drug maker | Mylan | India | US | HIV/AIDS patients |
blog comments powered by Disqus
  • Wed, Aug 27 2014. 05 55 PM
  • Wed, Aug 20 2014. 07 26 PM
ALSO READ close

Mylan plans direct entry into India

Subscribe |  Contact Us  |  mint Code  |  Privacy policy  |  Terms of Use  |  Advertising  |  Mint Apps  |  About HT Media  |  Jobs
Contact Us
Copyright © 2014 HT Media All Rights Reserved